Which dengue vaccine is Merck developing or marketing?
Merck’s dengue work has been tied to the company’s broader vaccine pipeline, but the exact product name depends on what you mean by “dengue vaccine” in your question. Merck has previously had dengue vaccine activity through its portfolio and collaborations, yet the best-known dengue vaccines are different companies’ products.
If you meant the commonly referenced dengue vaccines, they are typically:
- Takeda’s Dengvaxia (dengue vaccine)
- Sanofi’s Qdenga (dengue vaccine)
Merck is often discussed more in the context of pipeline activity, partnerships, or individual candidate programs rather than as the primary manufacturer of the two widely used dengue vaccines.
What is “v181” in this context?
“V181” can refer to a specific vaccine program or candidate designation used in public disclosures, trial registries, or press materials. Without an official name (for example, the full candidate name, target indication, or a link to the announcement/trial), it’s hard to map “v181” to the correct Merck program and confirm whether it is dengue-related.
If you share where you saw “v181” (a news link, clinical trial registry ID like NCT number, or the full company/candidate label), I can identify:
- whether it is dengue-specific
- which company owns it (Merck vs partner)
- the trial phase and geography
How do Merck and dengue vaccine candidates typically fit together (company vs candidate ownership)?
For vaccine programs, it’s common that:
- the sponsor/manufacturer is one company,
- while trial execution involves partners and contract organizations,
- and IP ownership can be separate from branding/marketing rights.
So “Merck and (dengue vaccine or v181)” might be pointing to either:
- Merck as the developer/sponsor of a dengue candidate, or
- Merck as the commercial partner/market presence for a vaccine developed by someone else.
What patients and clinicians usually want to know about dengue vaccines
People searching dengue vaccine information usually focus on:
- who is eligible (age ranges, prior infection status where relevant),
- how many doses and the dosing schedule,
- effectiveness by dengue strain and prior exposure,
- safety signals and how they compare across vaccines.
If you tell me whether you mean Dengvaxia, Qdenga, or a Merck-specific candidate (the “v181” label), I can answer those points for the specific vaccine.
Next step: confirm the exact product or candidate
Reply with one of the following and I’ll pin down the Merck/dengue relationship precisely:
- the full candidate name that includes “V181”
- a clinical trial ID (NCT number / registry link)
- whether you mean Dengvaxia, Qdenga, or another dengue vaccine
- the country or context where you saw “Merck” mentioned with “v181”